CABG Medical Announces Approval to Expand Clinical Trials Into Europe
03 June 2005 - 11:15PM
PR Newswire (US)
CABG Medical Announces Approval to Expand Clinical Trials Into
Europe MINNEAPOLIS, June 3 /PRNewswire-FirstCall/ -- CABG Medical,
Inc. (NASDAQ:CABG) today announced it has received approval from
regulatory authorities to evaluate the Holly Graft System in
clinical trials at various centers in Germany. The Holly Graft(TM)
System, is a drug eluting graft (DEG) for facilitating a coronary
artery bypass procedure. (Logo:
http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO ) "The
approval to begin clinical trials in Germany allows us to begin the
evaluation of our technology in what we believe will be the third
largest worldwide market for the Holly Graft System," said Manny
Villafana, Chairman and CEO. "The approval to begin clinical trials
represents a tremendous opportunity for CABG Medical to begin
working with some of the largest hospitals in the world and on
expanded base of qualified physicians." The clinical trial is
designed to collect and analyze "real-world" clinical outcomes data
for CABG Medical's Holly Graft(TM), a paclitaxel- eluting graft
system in the treatment of patients with coronary artery disease
Also, the Company announced today, that Dr. Peter Tesar of the
Prince Charles Hospital in Brisbane, Australia will be presenting
an overview of the Company's DEG clinical trial program at the
Annual Scientific Meeting of the International Society for
Minimally Invasive Cardiothoracic Surgery (ISMICS) on June 4, in
New York. The meeting is by invitation only and will be held at the
Marriott Marquis. About CABG Medical CABG Medical, Inc. is a
medical technology company developing technologies and therapies to
improve the treatment of coronary heart disease by advancing
conventional bypass surgery. We have designed our first product,
the Holly Graft(TM) System, by leveraging our understanding of flow
dynamics, material sciences and drug combinations to create a DEG
system. Safe Harbor This Press Release contains forward-looking
statements that may include statements regarding intent, belief or
current expectations of the Company and its management. Actual
results could differ materially from those projected in the
forward-looking statements as a result of a number of important
factors, including regulatory actions, competition, and management
of growth. For a discussion of these and other risks and
uncertainties that could affect the Company's activities and
results, please refer to the Company's filings with the Securities
and Exchange Commission.
http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO
http://photoarchive.ap.org/ DATASOURCE: CABG Medical, Inc. CONTACT:
Manny Villafana, Chairman & CEO, or John L. Babitt, President
& COO, both of CABG Medical, Inc., +1-763-258-8005, Fax:
+1-763-258-8008 Web site: http://www.cabgmedical.com/
Copyright
Cabg Medical (NASDAQ:CABG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cabg Medical (NASDAQ:CABG)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Cabg Medical (MM) (NASDAQ): 0 recent articles
More Cabg Medical (MM) News Articles